Wistar Scientist Is Chair Of 1998 American Association For Cancer Research Program Committee

March 12, 1998

Philadelphia--Frank J. Rauscher III, Ph.D., professor and head of The Wistar Institute's Molecular Genetics Program, has been named Chair of the 89th Annual Meeting of the American Association for Cancer Research (AACR), to be held March 28-April 1, 1998 in New Orleans. He also is Chair of the Plenary Session on New Horizons in Cancer Research, which will survey the latest advances in cancer detection and treatment.

The purpose of the annual AACR meeting is to bring together scientists from around the world to discuss the latest developments in basic, clinical and translational cancer research. The Philadelphia-based AACR has a worldwide membership of over 14,000 cancer researchers, with more than 7,500 expected to attend this year's program.

The meeting will feature 4,500 abstracts and approximately 200 presentations. It also will include a special late-breaking research session that will feature important findings of the past several months.

Some of the discoveries to be discussed are identification of a hereditary gastric cancer gene, a serum protein that may be useful for assessing prostate cancer risk, and the prevention of lung cancer with the use of aerosol inhalants.

Dr. Rauscher is widely recognized in the scientific community for his ground-breaking research on Wilms' tumor, a kidney cancer typically diagnosed in children under the age of six. It affects one in 10,000 newborns worldwide and is caused by a malfunction of the Wilms' tumor 1 gene (WT1).

Just recently, Dr. Rauscher and his Wistar research team, working in collaboration with a group of international scientists, identified a new gene, BAP1, which is associated with breast and lung cancer development. The discovery of BAP1 makes it possible to do genetic testing for its presence, making it a potential target for drugs that combat breast and lung cancers.

Dr. Rauscher, whose research centers on gene regulation and molecular oncology, has worked at The Wistar Institute since 1990. He currently serves as Associate Editor of Cancer Research, is on the editorial board of Cell Growth & Differentiation and on the editorial academy of the International Journal of Oncology. He is a manuscript reviewer for roughly 30 scientific journals, and is a reviewer for the State of New Jersey Commission on Cancer Research and the United States-Israeli Binational Science Foundation.

Among his many other activities, Dr. Rauscher is an established investigator in the Molecular Approaches to Pediatric-Science Child Health Research Center at The Children's Hospital of Philadelphia, and at The Penn Center for Molecular Studies of Kidney Diseases.

The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.


The Wistar Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.